GET DAILY SIGNALSDelcath Systems (DCTH): Why the $26 Analyst Target Implies +74% Upside
Key Takeaways
- The central $26 stock price target is the arithmetic mean of five recently updated analyst targets, which range from $21 to $32.
- With shares recently near $14.93, reaching $26 would require a gain of roughly 74%, a very large move.
- Analysts are uniformly constructive, with Buy-equivalent ratings across the coverage reviewed and no Hold or Sell ratings.
- Supporting factors include a sharp third-quarter revenue and earnings beat and raised 2026 revenue guidance.
- The biggest risks are commercial execution, reliance on a single product line, and the stock's history of sharp, news-driven swings.
- For more context, explore Major News, Today's Price Move, Forecast, and Earnings pages for this ticker.
- Discover Trending AI Robots to see how automated, AI-driven strategies track opportunities like this one.
Analyst Price Targets and Consensus View
Delcath Systems, Inc. (DCTH) is an interventional oncology company whose lead product, HEPZATO KIT, delivers high-dose chemotherapy directly to the liver to treat metastatic uveal melanoma and other liver cancers. Five recently updated analyst price targets were reviewed to establish the central target: H.C. Wainwright at $32, Clear Street at $27, BTIG at $25, Craig-Hallum at $24, and Canaccord Genuity at $21. The arithmetic mean of these five figures is approximately $25.80, which rounds to a $26 average analyst price target.
The spread between the low ($21) and high ($32) is unusually wide, reflecting genuine disagreement about how quickly the company can scale HEPZATO adoption. H.C. Wainwright raised its target to $32 from $30 in August 2026, while Craig-Hallum lifted its target to $24 from $18 and BTIG moved to $25 from $21. Canaccord has maintained $21, and Clear Street previously lowered its target to $27 from $29. This mixed pattern of upgrades and trims shows that analysts are encouraged by accelerating revenue but mindful of execution and spending risks. The $26 figure is a calculated average, not an officially published consensus. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
With the stock recently near $14.93, a move to $26 would require about 74% upside — a very large move even for a high-growth small-cap. The path is visible but demanding. Delcath reported third-quarter 2026 revenue of $35.1 million, well above the roughly $26 million consensus, and raised full-year 2026 revenue guidance to $115–$117 million from prior expectations. Management has also pointed to expanding treatment centers, targeting roughly 37 sites by year-end from 31 in mid-2026, and to a growing shift toward combination and sequencing therapy that extends patient treatment duration. Sustained execution on these fronts would be needed to support a substantially higher valuation.
What Could Support a Move Toward the Target
Several verifiable factors underpin the bullish case. HEPZATO KIT delivered gross margins near 90%, giving the model strong operating leverage as revenue scales. The company is broadening its pipeline through Phase 2 trials in metastatic colorectal cancer and HER2-negative metastatic breast cancer, and its CHOPIN trial results were published in The Lancet Oncology. A cash position of roughly $96 million at mid-2026, together with a $25 million share buyback, provides balance-sheet flexibility. Most importantly, recent quarterly results beat expectations on both the top and bottom lines, and management raised guidance — the kind of fundamental momentum that typically supports a higher stock forecast.
What Could Prevent the Target From Being Reached
The risks are equally real. Delcath remains essentially a single-product company, so any slowdown in HEPZATO adoption, new patient starts, or treatment-center capacity would disproportionately hurt results. The introduction of 340B pricing has already reduced the effective average selling price per kit, a headwind analysts continue to monitor. Higher R&D and SG&A spending to fund trials and commercial expansion may pressure near-term profitability. The shares have also fallen roughly 14% over the past three months despite the strong quarter, underscoring how volatile the stock can be around quarterly updates and clinical news.
Technical Levels and Market Structure
From a technical perspective, the stock has traded in a wide range over the past year, with a 52-week span roughly between $8 and $18. The $26 target sits well above that prior peak, meaning the shares would first need to reclaim and hold above the prior highs near $18 before a $26 level could become realistic. That overhead supply, combined with the stock's tendency for sharp reactions to earnings and trial data, makes the path to $26 more of a multi-stage advance than a straight line.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a roughly 12-month research horizon, though individual firms do not always state an explicit timeframe. Investors should watch quarterly HEPZATO revenue and new patient starts, updates on treatment-center expansion, progress in the colorectal and breast cancer trials, any further guidance revisions, and changes to analyst price targets. Regulatory and reimbursement developments, including 340B pricing dynamics, also remain relevant to the long-term market outlook.
Final Assessment
The question of whether DCTH can reach $26 hinges on sustained commercial execution rather than a single catalyst. The target, a calculated average of five analyst targets spanning $21 to $32, implies roughly 74% upside from recent levels — a very large move. Strong recent revenue, raised guidance, and high gross margins provide a credible foundation, while single-product concentration, pricing pressure, rising costs, and technical overhead near prior highs present meaningful obstacles. With analyst opinion uniformly constructive but spread across a wide range, investors should track quarterly adoption metrics and clinical progress closely rather than treating the $26 figure as a forecast.
Exploring Tickeron’s AI Daily Buy/Sell Signals
In my research process, I often turn to Tickeron’s AI Daily Buy/Sell Signals to get an additional layer of insight. The tool applies artificial intelligence to scan thousands of stocks and ETFs in real time, producing Buy, Sell, or Hold signals based on technical patterns, market conditions, and broader trend analysis. It helps me spot momentum shifts more efficiently than manual review alone, and I find it useful for cross-checking ideas around names like DCTH without replacing my own fundamental work.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
DCTH in downward trend: 10-day moving average broke below 50-day moving average on October 06, 2026
The 10-day moving average for DCTH crossed bearishly below the 50-day moving average on October 06, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
DCTH moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DCTH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
The Aroon Indicator for DCTH entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where DCTH's RSI Indicator exited the oversold zone, 28 of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 49 of 62 cases where DCTH's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on DCTH as a result. In 76 of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.
The Moving Average Convergence Divergence (MACD) for DCTH just turned positive on November 04, 2026. Looking at past instances where DCTH's MACD turned positive, the stock continued to rise in 33 of 39 cases over the following month. The odds of a continued upward trend are 85%.
Following a +3.71% 3-day Advance, the price is estimated to grow further. Considering data from situations where DCTH advanced for three days, in 198 of 248 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
DCTH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. DCTH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 61 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron SMR rating for this company is 90 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 97 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.276) is normal, around the industry mean (4.142). DCTH's P/E Ratio (1493.000) is considerably higher than the industry average of (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (6.757) is also within normal values, averaging (40.124).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices
Advertisement